Facebook
X
LinkedIn
Forward
11th Annual Updates from ASH 2025: Practice-Changing Abstracts
Chicago, IL US
January 30, 2026
Advance your practice in hematologic malignancies with cutting-edge Insights from leading experts!
Join a dynamic educational forum designed to connect community-based clinicians with academic oncologists and gain the latest insights into hematologic malignancies. This conference delivers rapid ASH updates on emerging clinical data and showcases early treatment options and groundbreaking advances, including CAR T-cell therapy, novel immunotherapies, targeted agents, and gene therapy, empowering you to provide state-of-the-art care for patients with both newly diagnosed and relapsed blood cancers.
Through expert-led presentations and interactive panels, you will:
- Stay current with the latest scientific data, innovative therapeutic strategies, and evolving safety considerations.
- Learn practical approaches for integrating and sequencing novel therapies in real-world settings.
- Explore management strategies for complex treatment toxicities, including bispecific therapies.
- Gain guidance on referral pathways, clinical trials, and gene therapy options for your patients.
This essential educational experience equips you with actionable strategies to enhance patient management, optimize interdisciplinary care, and improve outcomes. Don’t miss this opportunity to access rapidly evolving, potentially lifesaving knowledge that directly impacts patient survival and quality of life.
Target Audience
This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and all healthcare professionals dedicated to the treatment of hematologic cancers.
Learning Objectives
After this activity, participants will be able to:
- Summarize key clinical and scientific advances presented at the 2025 ASH Annual Meeting that have the potential to change practice in hematologic malignancies.
- Determine appropriate patient selection, timing, and sequencing for transplantation and cellular therapies in high-risk hematologic diseases.
- Integrate novel therapeutic agents and combinations into standard-of-care treatment pathways for patients with myeloid, lymphoid, and plasma cell disorders.
- Evaluate emerging targeted and cellular therapies, including CAR T-cell and bispecific antibody approaches, for patients with relapsed or refractory hematologic malignancies.
- Formulate practical strategies to overcome barriers to implementing evidence-based innovations in community-based hematology & oncology practice.
You may also be interested in
| Time | Session | Faculty |
|---|---|---|
| 7:00 AM | Breakfast, Exhibits, & Registration | |
| 8:00 AM | Welcome & Orientation | |
| 8:10 AM | Top 5 Breakthroughs from ASH 2025 | Rafael Madero-Marroquin, MD Alexandra Rojek, MD Elijah Darnell, MD Adam Stepanovic, MD Moderated by: Gregory Roloff, MD |
| 8:55 AM | Updates in Managing HM Pharmacologic Conditions | Jennifer Collins, PharmD, BCOP Moderated by: Kaitlin Kelly, PharmD |
| 9:25 AM | Myeloma Session | Yi Lin, MD |
| 9:55 AM | Case Study in Myeloma Panel: The Role of Bispecifics in Myeloma Therapy | Yi Lin, MD, Jennifer Cooperrider, MD Moderated by: Benjamin Derman, MD |
| 10:35 AM | Break & Exhibits | |
| 11:05 AM | Gene Therapy & Non-Malignant Hematology & Sickle Cell | Moderated by: Satyajit Kosuri, MD |
| 11:50 AM | Networking Lunches | |
| 1:00 PM | Acute Lymphoblastic Leukemia in Adults: Emerging Innovations and Clinical Impact | Marlise Luskin, MD |
| 1:50 PM | Leukemia Panel | Marlise Luskin, MD, Gregory Roloff, MD Moderated by: Anand Patel, MD |
| 2:30 PM | Bispecific Toxicities Panel | Kaitlin Kelly, PharmD, Divya Khandekar, PharmD, BCOP Moderated by: Jennifer Collins, PharmD, BCOP |
| 3:00 PM | Break & Exhibits | |
| 3:30 PM | Lymphoma Session | Brad Kahl, MD |
| 4:00 PM | Case Study in Lymphoma Panel: The Role of Bispecifics and CAR-T Therapies | Brad Kahl, MD Moderated by: Justin Kline, MD |
| 4:40 PM | Top 10 Takeaways from Post-ASH | Rafael Madero-Marroquin, MD Alexandra Rojek, MD Elijah Darnell, MD Gregory Roloff, MD Adam Stepanovic, MD Moderated by: Michael Bishop, MD |
| 5:00 PM | Thank You & Closing Remarks | Michael Bishop, MD |
| 5:00 PM | Reception | |
| 6:00 PM | Adjourn |
The agenda is subject to change.
Swissotel Chicago
323 East Wacker Drive
Chicago, IL
60601
United States
HYBRID CONFERENCE
Participants can attend in person or virtually. For more information, visit the conference website or contact us via email.
SWISSOTEL CHICAGO
Designed by renowned Chicago architect Harry Weese, Swissôtel Chicago is an award-winning luxury hotel overlooking the Chicago River and Lake Michigan, and just steps from the Magnificent Mile. The distinctive 4-diamond, all-glass hotel offers spectacular wrap-around views from Navy Pier to Millennium Park, 662 guest rooms and suites, five premier ballrooms, a state-of-the-art penthouse fitness center, and spotless European-style service.
VISITING CHICAGO
Discover why Condé Nast Traveler readers voted Chicago the Best Big City in the U.S. for a historic ninth year in a row. To help plan your stay in Chicago, visit Choose Chicago.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Meeting Achievements via email.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, the University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO COURSE DIRECTOR
Michael R. Bishop, MD
Professor of Medicine
Director, Jonas Center for Cellular Therapy
Director, Hematopoietic Stem Cell Transplantation Program
Professor of Medicine
Director, Jonas Center for Cellular Therapy
Director, Hematopoietic Stem Cell Transplantation Program
Disclosure Declarations
As a provider accredited by the ACCME, the University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an educational activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, the University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an educational activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 6.75 contact hours.
American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months may incur additional fees.
EXHIBIT OPPORTUNITIES ARE AVAILABLE! SPACE IS LIMITED, SO SIGN UP TODAY!
Put your organization at the forefront of hematologic oncology innovation. This conference offers exhibitors a unique opportunity to engage directly with influential clinicians and decision-makers shaping the future of hematologic oncology.
Why Exhibit?
- Showcase your therapies, technologies, and patient support solutions.
- Connect directly with clinicians implementing the latest advances in myeloid, lymphoid, and plasma cell disorders.
- Gain brand visibility through one-on-one connections during breaks or prominent brand visibility in the event program.
- Engage with decision-makers eager for real-world strategies to improve patient care.
Space is limited, so secure your exhibitor spot today! Download the 
prospectus or contact Meeting Achievements by email or phone at 219-465-1115. We hope to see you there!
prospectus or contact Meeting Achievements by email or phone at 219-465-1115. We hope to see you there!
REGISTRATION
Early rates expire on December 19, and space is limited, so reserve your spot today!
Profession Type | In Person | Virtual |
|---|---|---|
Physicians | $100/$125 | $50/$60 |
Nurses, Pharmacists, Other Healthcare Professionals | $45/$60 | $30/$40 |
Residents & Fellows | $25 | $25 |
| UChicago Faculty & Staff | $25 | $0 |
| Industry | $495 | $195 |
CANCELLATION POLICY Please see the registration site for the full details. | ||
Claiming Credit: After creating an account or logging in, enter the access code to unlock the credit claiming process.
Please note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months may incur additional fees.
Please note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months may incur additional fees.
Please login or create an account to proceed.